UBS Downgrades Acadia Pharmaceuticals to Neutral, Lowers Price Target to $23
UBS analyst Ashwani Verma downgrades Acadia Pharmaceuticals (NASDAQ:ACAD) from Buy to Neutral and lowers the price target from $49 to $23.
Stocks · News reference
U.S. stocks fell Thursday: Dow -0.7%, S&P 500 -0.46%, Nasdaq -0.7%. Oil jumped 4.4%; Darden missed estimates, while APUS surged 163%.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
UBS analyst Ashwani Verma downgrades Acadia Pharmaceuticals (NASDAQ:ACAD) from Buy to Neutral and lowers the price target from $49 to $23.
RBC Capital analyst Brian Abrahams maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price target from $37 to $36.
https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-allowance-of-u-s--patent-covering-weight-banded-dosing-of-trofinetide-extending-u-s--patent-protections-to-march-2041
Filed: 2026-10-13 AccNo: 0001213900-26-108780 Size: 238 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
MindWave Innovations Inc. USA, a subsidiary of Apimeds Pharmaceuticals US, Inc., signed three blockchain network agreements within 10 days with AQUAE Holdings (climate finance), Flash Sports & Media Holdings (sports media), and BlockAssure Inc. (insurance). Each agreement follows the same model where MindWave builds and operates dedicated MindChain networks while receiving 20% token/credit allocations. However, the parent company disclosed substantial doubt about its ability to continue as a going concern.